Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks, Life1.
Ann
Stock:
"Preciouslife1--Was at the meeting and talked with Tony Frudakis in private..."
Do you know this for sure? Just curious.
Take care,
Ann
DNAPrint(R) Genomics Announces Acceptance of Studies for Publication
Market Wire
Posted: 2007-07-09 07:13:48
SARASOTA, FL -- (MARKET WIRE) -- 07/09/07 -- DNAPrint® Genomics (OTCBB: DNAG), which holds two patents and has seven patent applications pending related to genetic markers, today announced that two studies performed by Company Founder and Chief Science Officer Tony Frudakis, Ph.D., will be published in peer reviewed scientific journals in the coming months.
"Multilocus OCA2 Genotypes Specify Human Iris Colors," which describes the identification of numerous new OCA2 single nucleotide polymorphism (SNP) associations with iris color and how they can be used together to predict iris color from DNA, will be published in the journal Human Genetics, a respected peer-review journal which publishes the latest research in the field.
The methods for making these predictions are part of the Company's patent-pending platform for empirically relating genotypes to phenotypes.
According to one reviewer, the manuscript "illustrates: 1) fine-phenotyping of a complex trait helps dissect the genetic factors that influence the trait; 2) simplistic interpretations for many traits will arise if the scientific community limits its studies of loci to a few associated SNPs and haplotypes." Another reviewer stated that "...this is an interesting paper. OCA2 and iris pigmentation is a great model for studying the effects of genetic variation on a complex trait."
DNAPrint's ancestry technology was crucial for identifying SNPs truly associated with iris color, as opposed to those merely correlated with iris color due to ancestry informativeness (since ancestry is itself correlated with iris color). In addition, the Company's patented Haploscope software system was crucial for identifying the most informative haplotypes.
Described for the first time in this manuscript, the method is also described in more detail in a textbook written by Dr. Frudakis to be released later in 2007.
Another article by Dr. Frudakis that describes a polymorphism associated mainly with Lipitor®-induced myalgia, originally scheduled for publication in November 2006 in the scientific journal Pharmacogenetics and Genomics, will now be published in August 2007. The journal gave no reason for the delay in publication.
Dr. Frudakis founded the company that eventually became DNAPrint® in 1998, serving as its president and chief executive officer. Prior to this, Dr. Frudakis was a research scientist for Corixa Corporation. In all, his work has resulted in a patent portfolio for over 350 unique genes and two products. Dr. Frudakis is a Phi Beta Kappa, magna cum laude graduate of the University of California Irvine where he received a bachelor's degree in biological sciences. His doctorate in molecular and cell biology is from the University of California Berkeley. Today, Dr. Frudakis is the Chief Science Officer, Director and founder of the company. Mr. Richard Gabriel has assumed the role of President and Chief Executive Officer.
About DNAPrint(TM) Genomics, Inc.
DNAPrint Genomics, Inc. ( www.dnaprint.com ) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Ann
By Work2play (IV):
"Steinburger...I sat in on a roundtable discussion with Dr. Frudakis back in 2002 in Chicago. What I remember most about that meeting was the confidence he had in what they were doing at DNAPrint. And from all of the associations they've formed since 2002 and all of the collaborative projects they're working on with world renowned researchers I just have a very difficult time believing that there is no value in their science. Just doesn't make sense to me. So if it's not the value of the science, why else would they not have partnered by now?
I also attended the shareholders meeting in 2003. I remember the discussion concerning the Orchid Option and what a hindrance that posed for partnering. If you've never read the Option, I would recommend it. The thing really is draconian. The Option had a seven year life so should expire this September.
JMHO, but it seems to me as though everything they've been doing points to September/October 2007. Read their agreements, look at the way the Biofrontera shares were sold and the timing of the payments, look at the option they maintained to repurchase the Biofrontera shares, look at the most recent consulting agreement with Athena Capital, look at the timing of M2Gen and the Conference in the Carribean this fall. Heck, even the timing of Tony's book.
Of course I could be completely wrong and September may come and go with a fizzle (actually, I'm giving it until November 2007). But IMO, if we don't see something significant by then, we will likely never see it.
And lastly, don't let the trashers get you down. They're just pathetic little people with no hopes or dreams who probably never took a REAL chance on anything. Not on anything GOOD anyway.
No matter how this works out in the end, I have the satisfaction of knowing that my support helped keep them in business long enough to take several serial murderers off the streets (among a myriad of other worthy contributions to science). Frankly, if that's all I ever get for my investment, it was money well spent.
God Bless and Take Care My Friend,
W2P
Ann
House OKs Bill to Improve Drug Safety
ByANDREW BRIDGES,AP
Posted: 2007-07-11 20:47:35
WASHINGTON (AP) - Seeking to avoid another Vioxx debacle, the House voted overwhelmingly Wednesday to give federal health officials more money and power to police the safety of prescription drugs.
The House approved 403-16 a bill giving the Food and Drug Administration nearly $400 million, collected as fees from the drug industry, to spend on drug safety over the next five years. The Senate already has approved similar legislation.
Both bills would give the agency the ability to require drug companies to do follow-up studies on certain medicines.
"It's become increasingly clear FDA needs more of two things: It needs more resources and more authority, particularly in the area of postmarketing surveillance," said Rep. Henry Waxman, D-Calif.
The House version would require the FDA to review the safety of certain drugs annually for the first three years following approval and then again during the seventh year. It also would require drug ads to include a toll-free number and Web address for consumers to report side effects and would permit only a single outside expert with a potential conflict of interest to be cleared to serve on any agency advisory panel.
Rep. Michael Burgess, R-Texas, criticized the restriction on those outside advisers, noting it's already difficult to find scientists who are experts in some fields.
"This irrational standard will only make it harder," said Burgess. Burgess also praised the earlier stripping out of a provision that would have limited drug companies from advertising new drugs directly to consumers. Such a limit had raised free speech concerns.
The FDA was criticized for being too slow to respond once serious problems were linked to the painkiller Vioxx. Merck & Co. Inc. voluntarily withdrew the drug in 2004 after research showed it doubled the risk of heart attacks and strokes.
The legislation's underlying purpose is to renew, through 2012, a program that has the drug industry pay fees to the agency to defray the cost of reviewing new medicines. In the wake of the Vioxx withdrawal and subsequent problems with other drugs, lawmakers seized on the legislation to overhaul how the FDA handles the safety of the drugs it regulates. The bill gathers together other legislation as well, including the reauthorization of a medical device industry user fee program.
The House bill also would give the FDA authority to require further studies of drugs after they're already on the market - and require pharmaceutical companies to submit timetables for their completion. The FDA also could order label changes to a drug or restrict its use or distribution.
Both the House and Senate bills require the FDA to increase its active surveillance of emerging problems with drugs. The bills call for the mining of large health care databases for signs of unanticipated drug side effects.
Rep. John Dingell, D-Mich., said the goal there was "reducing the likelihood of another Vioxx situation, when reported adverse effects went unheard."
The House and Senate are expected to resolve the differences between the versions in coming weeks.
The Senate earlier voided - and the House didn't include at all - a provision that would have allowed consumers to buy cheaper prescription drugs from abroad. The White House has threatened to veto the FDA bill if it contains such a provision.
Ann
"Moving beyond its existing genetic ancestry testing business puts DNAPrint Genomics (OTC: DNAG) on the road to genomic medicine, says CEO Richard Gabriel. "People are trying to figure out what personalized medicine means," he explains. "We've proven the technology, now it's just a matter of capital." Revenue from the company's consumer ancestry and forensic genetic screening business is on the rise; some equity funding is in place, and strategic equity sales may help raise cash. "Our product is more effective, less toxic, and we will link it to genetic ancestry as well as other diagnostics."
Ann
Wallstreet Reporter interview:
http://www.wallstreetreporter.com/profile.php?id=24029
Ann
Thanks, Grant!
Ann
Cottonpicker:
You are dead wrong when you recall meeting me at a BIFT meeting and have me confused w/someone else for sure. Please, do not bring me into that scenario.
Ann
Merck/Moffit join foreces:
http://www.sptimes.com/2006/12/19/Tampabay/Moffitt__Merck_join_f.shtml
Ann
Small Cap Discovery Conference Interview:
http://www.wallstreetreporter.com/profile.php?id=24029
Ann
Interesting DNAP tie-into Orchid:
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/12-14-2004/0002630779&...
Ann
1USGrant:
I'm glad someone agrees w/me re: Chrisbasketcase!
Good luck to you,
Ann
Chris:
"unusual if not annoying way to describe blatant lying"
IMHO opinion - Stockhldr isn't lying - he's simply expressing himself, his opinions, ideas, occasionally making calls and contacts and sharing certain updates with us, (even if sometimes sounding idyllic. He has that right, even if you "incessantly" disagree.
In all the years I've spent on this board with you, Chris, I have "never" seen you post one thing (nothing ever) where you have done an internet search for information relating to DNAG, where many of us take time,effort into the tasks of find/search/post/comment/share.
Now,.......Can I see your credentials, Chris?
Take care,
Ann
Interesting: Gavin Menzies & DNAP:
http://www.sys-con.com/read/246947.htm
Ann
Good luck to you, Theo!
Ann
Arch Personal Care website (one of the collaborators):
http://www.archchemicals.com/Fed/PC
Ann
Theo - what I posted on Genelink/DNAP - is the only link I find. Perhaps someone else can come up w/more current info.
Take care,
Ann
Theo:
Interesting - to refresh our memories, this was the collaborative agreement between Genelink & DNAP:
GENELINK PARTNERS WITH DNAPRINT TO DEVELOP "NEXT GENERATION" GENETIC-PROFILE TESTS FOR PERSONALIZED COSMETICS
MARGATE, NJ - BUSINESS WIRE - March 6, 2003 - GeneLink, Inc. (OTCBB:GNLK) announced today that it entered into a collaborative agreement with DNAPrint Genomics, Inc. (OTCBB:DNAP) whereby the companies will combine certain scientific and intellectual property resources to develop and market "next generation" genetic profile tests to the $100 Billion plus personal care and cosmetics industry. Further details were not disclosed.
GeneLink invented the first genetically-designed patentable DNA test for customized skin-care products, and DNAPrint brings its ultra-high throughput genotype capability and ADMIXMAP platform to the partnership. The companies anticipate screening millions of candidate markers to broaden proprietary product offerings.
Tests are designed to assess genetic risks for certain skin and nutritional deficiencies and provide a basis for recommending formulations that have been specifically designed to compensate for these deficiencies.
Rather than offering a "stand alone" genetic test, DNAPrint, GeneLink and other collaborative partner(s) (such as Arch Personal Care Products see news_articles) will link genetic assessments to a personalized solution for certain common dermatological and skin-aging problems. Current and future products are being offered to leading cosmetic industry marketers and manufacturers.
"GeneLink's Dermagenetics technologies are a breakthrough for the skin-care industry; they provide a viable means by which to personalize the selection of skin care products," says Tony Frudakis, DNAPrint's CEO. "We are very pleased to work together with GeneLink to co-develop new genetic assessments for a ready market place".
"DNAPrint is the leader in the measurement of population structures for disease genetics. GeneLink sees a significant opportunity to expand our industry leadership and patentable positions by combining scientific technologies with DNAPrint's ADMIXMAP capabilities," says John DePhillipo, GeneLink's CEO. He added, "By broadening our services and licensing opportunities, we increase immediate and future income opportunities for both companies."
Ann
Frog:
OT:
With Pinnochio it was the nose...
with you, it's the warts!!
Ann
Scott:
I've "always" believed in Tony Frudakis' inherant capabilies, achievements, capabilities & support. Tony Frudakis is a unique, omni-talented man of science in the field of computational theranostics, who is focused on accomplishing his achievements & participation of technological challenges! Most fortunately, in my opinion, he seems inherently aware of the sensitivity of shareholder value & support, those that have stood steadfast behind him for so many years and, so, with dignity & gratitude, he perceives the need to reward the investors with fair & higher shareholder values, - an outlook which is rare these days especially for the "Pinks." He is a unique, high-thoroughput, talented professional, not to mention his great capabilities as a developer of cutting edge technologies. He comes across as someone who is sincere and dedicated at every turn of his scientific endeavors. His achievements are not only invasive in the technology of sciences, but venture to the utmost delivery of benefiting of people from every makeup of the world. I would cast my vote for Tony Frudakis for the Nobel Peace Prize at the drop of a hat and hope that someday he will be rewarded as the receipient of one of the greatest achievements to mankind! JMHO
Take care,
Ann
Ann
YES!!
Ann
Shareholder's Meeting Presentation - '07 - from website:
http://www.dnaprint.com/welcome/investorrelations/presentations/
Ann
Precious:
"I personally am getting in touch with several financial institutions such as Raymond James, BOA and a money manager who manages Paul Allen's assets in Seattle..that call is next..."
Good for you! I will cross my fingers & my toes! & Thank you, in our behalf!
Take care,
Ann
Oops sorry - '06 NOT '07 meeting.
I guess I'm entitled to a mistake once in a while. - lol
Ann
'07 - Shareholder's meeting from Richard Gabriel:
http://www.primenewswire.com/newsroom/news.html?d=101142
Ann
DNAP's Father's Day gift:
http://www.primenewswire.com/newsroom/news.html?d=100858
Ann
Onco:
Hope our tunnel is not too long!
Take care,
Ann
More on the Shareholder's Meeting (by Ebo/IV):
"A little more from the meeting:
I have some more time now that I’m relaxing in Philadelphia. Watched some fireworks last night. They celebrate the 4th of July all week here.
Some more answers to the questions about the annual meeting:
“Did Gabriel talk about why he thinks DNAG can get non-toxic financing when have not been able to do so in the past?”
As I mentioned before, the financial environment is getting better and the bankers more friendly. PIPEs are out; RS's are out. The SEC wants eliminate those toxic finance schemes. They are changing various rules such as rule 144: http://reverseshellmerger.com/2007/06/26/sec-rule-144-proposal-for-sale-of-shell-shares/
That’s all we can say about that.
“Can you tell us how many people attended the meeting?“
There were six DNAG employees. The number of shareholders were, by my estimate, about 30.
“Did you get a sense of how much financing they need and by when they need it before DNAG can not continue?”
You have read PL1 ‘s explanation of $30 million needed, which was expressed to him by Gabriel. I have every reason to have faith in that explanation. During the actual meeting, he answered what the minimum he would need and by when. I will reiterate my take as: They think that $5 million will finish the Protectin [CD59] diabetes test by 2008. They think that $10 million will finish the marvelous Super EPO [PT 401] and provide an NDA by 2010 with revenues flowing in 2011. This $15 million will be from the Spin-outs of the two entities (unless any of you could offer to invest that much instead). Those spin-outs could not happen before the end of the year, it is thought. They were asked, how much longer till you run out of money if you don't get the new funds? Answer: around November. Then, how much do you need to bridge you over until you can effect a spin-out and get the need funding? Answer: $3 million but bridge loans also carry a very high interest.
“Is there a timeline for spinning off DNAPP?”
The timeline is as soon as possible but, the environment necessary time to put it together and the necessary rule changes will not all come together until the end of 2007. That is why you hear of running out of money by November and the need for a bridge loan, etc.
“Does DNAG feel big pharma is trying to stall DNAG into bankruptcy?”
That was never stated as such. However, Tony did relate to us about the next article he had submitted to a peer reviewed journal to be published. It was supposed to be published a few months ago and he kept asking about it. Finally they said they were waiting for his response to questions that they requested a while back. He had sent the response immediately after they requested it in the first place, so he resent it to them. They said they had “lost” it. Since that had never happened to him, he did wonder why and if there was any one trying to influence the editors? The article is about Statinome and we should see it in the next month or so. Then, judge for yourself if you think a big pharma might have tried to keep it out of publication.
“Why does DNAG feel a deep pockets partnership has not yet occured?”
Tony is as frustrated as we are that there has not been more interest in partnering on one product or another. They have tremendous technology and have been able to do/show everything they said they could. My opinion is the same as PL1 has talked about. Tony & Co. has been so “leading edge” that most do not understand the potential. The FDA is just now coming around to understanding and finally trying to encourage the industry to use pharmacogenomics. Finally, I believe, as many of you, that big pharma really is trying to ignore/cover up anything like this. They absolutely do NOT want to focus their drugs on one part of the universe of potential patients. They have proven that they would rather have everyone use/try their drug (which ever one) and “maybe” pay for the ones who are killed or injured by it in return for the multi-billion dollar per year revenues.
”Is DNAG willing to be bought out?”
Everything is for sale at the right price. That being said, Tony knows what he has. He is NOT going to let it be bought out for pennies on the dollar. This is not a share of stock that he will sell for 50% or 500% over this extremely depressed and manipulated price; that’s trader mentality. Just as most of us did not get in this for a 100% profit, neither did he. We took the risk, it is high, and we expect a high reward. If you happen to be a trader then you don’t need to be reading this. This stuff is for “investors” as I prefer to call them. Buy, hold, get paid. Low risk, low reward; high risk high reward. I’m not leaving until I get my high reward.
Between PL1 and I, I think you have heard as much as we can say about the annual meeting. If there are other questions, I will be glad to answer them.
Keep in mind again:
1) The financial environment is getting better and the bankers more friendlily. PIPEs are out; RS's are out.
2) The FDA environment toward DNAG and genomics in general has become much better. The FDA is now on the same side as DNAG.
Ann
Interesting - Lee Moffit - You Tube on Esophagal cancer treatment:
Ok, Lugan.
Ann
Lugan:
Please reference/show the exact page you found that on. I could not find it on that website. Will be appreciated.
Take care,
Ann
Thanks, Sam:
I'm aware and have read and even posted same remarks in the past as I have been a shareholder since 2000. It's the financial breakthrough that seems to be stymied. Here we are awaiting an announcement (possible) on DNAP's involvement with M2gen, only to find out Merck is anti-DNAP. We just have to wait and see if anything develops in that area and perhaps, we shall overcome the obstacles...and make it!
Take care,
Ann
Precious:
"Dru Frudakis as well as Mr Gabriel both reiterated that Big Pharma does NOT like DNAprint, and their technologies as well as them squashing Tony's papers that he felt should have been published and out by now...."
That does not give us much hope, working w/M2gen, Merck, etc....
Ann
Is this you "once & for all" Frog:
DNAPrint changes symbol, gets sued: Yesterday, DNAPrint genomics, the genomics research and development company based in Sarasota, announced that as of today, its stock ticker symbol will official change from “DNAP” to “DNAG.” The symbol change is the result of the company’s recent stock consolidation. In other DNAPrint news, the company recently received a lawsuit with some pretty ugly claims against its top executives. The plaintiff, a Montana resident named Lonnie Bookbinder, alleges breach of contract, fraud, and conspiracy, among other claims, against the company, its CEO Richard Gabriel, its Chairman and Chief Medical Officer Hector Gomez, and a now-defunct company called Genbiomics. In the most simple terms, Bookbinder claims that the defendants essentially tricked Bookbinder into doing more than a thousand hours of consulting work for DNAPrint without compensating him properly as promised. The lawsuit was filed by attorney John Chapman of the Sarasota law firm Norton Hammersley Lopez and Skokos.
Mad:
I have no problem w/accessing the DNAP website.
Take care,
Ann
Michiko:
Please add Steinburger to the list.
Machine kaput.
Ann